Related Experiment Videos

Clinical trials of low-molecular-weight heparins in cardiology

S A Spinler1

  • 1Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Pennsylvania 19104, USA.

Pharmacotherapy
|December 28, 1999
PubMed

Insights

Investigating prognostic coagulation markers in acute coronary syndromes reveals evolving insights. Low-molecular-weight heparins show distinct effects, with enoxaparin offering economic benefits.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Acute coronary syndromes (ACS) pathophysiology is complex.
  • Prognostic coagulation markers play a crucial role in ACS.
  • Heparin anticoagulants, including unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs), are central to ACS management.

Purpose of the Study:

  • To explore the evolving understanding of ACS pathophysiology.
  • To investigate the impact of prognostic coagulation markers.
  • To compare the effects of UFH and LMWHs on these markers and review the economic evaluation of enoxaparin in ACS.

Main Methods:

  • Review of recent clinical trials involving LMWHs in ACS.
  • Analysis of the effects of different heparin types on coagulation markers.
  • Examination of economic evaluations for enoxaparin in ACS indications.

Main Results:

  • Emerging evidence highlights the significance of specific coagulation markers in ACS prognosis.
  • Low-molecular-weight heparins demonstrate differential effects on coagulation markers compared to UFH.
  • Enoxaparin presents a favorable economic profile for ACS treatment.

Conclusions:

  • The understanding of ACS pathophysiology is advancing with a focus on coagulation markers.
  • LMWHs offer a distinct therapeutic profile in ACS management.
  • Enoxaparin is a cost-effective option for treating acute coronary syndromes.

Related Concept Videos